Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

Denatured albumin is a potent ligand mediating platelet activaiton, adhesion and aggregation (ASH 2025) - "Inhibition of integrin αIIbβ3 (glycoprotein IIb/IIIa) using tirofiban or the 7E3 monoclonal antibodyabolished these force signals, identifying αIIbβ3 as the key receptor mediating platelet binding todenatured albumin...Using molecular engineering and platelet force imaging, we demonstrate that denatured albumin acts asa functional ligand for integrin αIIbβ3, promoting platelet activation, adhesion, and aggregation. Thisinteraction is mechanosensitive and specific to platelets.Given the high concentration of albumin in blood, even albumin denaturation at a low level, potentiallyinduced by oxidative stress, alcohol consumption, or pathological conditions such as diabetes, hepatitis,or sepsis, may have significant, previously unrecognized effects on platelet function and thrombotic risk.Our findings identify denatured albumin as a novel and strong regulator of platelet activity, opening newavenues in the understanding of thrombosis and hemostasis and therapeutic targeting..."

Cardiovascular • Diabetes • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Septic Shock • Thrombosis • VCL

Medical and perioperative management of acute and subacute heparin-induced thrombocytopenia in adults requiring urgent cardiopulmonary bypass surgery. (ASH 2025) - "After diagnosis of HIT, most were started on the alternative anticoagulants argatroban or bivalirudin(bival) in 0-1 days...These cases(each n=1) were not grouped: IO heparin+tirofiban with pre-op PLEX+IVIG, IO heparin alone, IO heparinwith pre-op plus IO PLEX, and 1 who died before planned surgery...IO bival appears to increase risk of IO and post-op bleeding but conclusions are limited bysample size. Larger, comparative studies are needed to determine and characterize the optimalmanagement approach for this unique clinical scenario."

Clinical • Surgery • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis

TEAR: Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair (clinicaltrials.gov) - P2/3 | N=192 | Completed | Sponsor: Beijing Tiantan Hospital | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Vascular Neurology

Factors influencing hemorrhagic transformation after mechanical thrombectomy for acute anterior circulation large vessel occlusion stroke and prediction modeling. (PubMed, Folia Neuropathol) - "Age, diabetes, NIHSS score on admission, time from onset to admission, time from onset to vascular recanalization, number of thrombectomy attempts, and use of tirofiban were independent risk factors for HT after MT in ALVOS patients. A logistic risk prediction model incorporating independent risk factors had some predictive value for HT after thrombolysis."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Hematological Disorders • Metabolic Disorders

INSIST-BT: Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (clinicaltrials.gov) - P3 | N=870 | Recruiting | Sponsor: General Hospital of Shenyang Military Region | Not yet recruiting ➔ Recruiting | Trial completion date: May 2027 ➔ Dec 2027 | Trial primary completion date: Mar 2027 ➔ Sep 2027

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "Adjunctive IC treatments during primary PCI do not influence hard clinical outcomes compared to conventional therapy within a mean 8-month follow-up, although several of them lead to an improvement in surrogate endpoints of CMVO."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis • Ventricular Tachycardia

Platelet membrane-camouflaged magnetic nano-formulations for improving acute thrombosis therapy. (PubMed, Colloids Surf B Biointerfaces) - "The platelet membrane-camouflaged magnetic nanoformulations have been fabricated as a dual-targeting nanocarrier for co-delivery the thrombolytic agent urokinase (UK) and the anticoagulant tirofiban (TF)...Additionally, the PMs camouflage provides the nanoparticles with "stealth" properties, allowing them to evade immune detection and clearance, thereby improving targeted delivery to thrombus sites and enhancing thrombolytic efficiency. In vivo studies confirmed that the TU-MMS@PP nanoformulations could rapidly restore blood flow at thrombosed sites within 30 min, demonstrating their potential as an effective antithrombotic therapy."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Safety and efficacy of short-term tirofiban combined with dual antiplatelet therapy after flow diverter placement for intracranial aneurysms: a multicenter retrospective study and nomogram for thromboembolic event prediction. (PubMed, Front Neurol) - "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard, yet clopidogrel resistance, especially in Asian populations, reduces efficacy. Tirofiban combined with DAPT in flow diverter treatment for intracranial aneurysms demonstrated good safety without increasing bleeding risk, though its efficacy advantage over DAPT alone was not evident. The proposed nomogram enables individualized TEE risk prediction and supports personalized antiplatelet management."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Vascular Neurology

Tirofiban-Induced Diffuse Alveolar Hemorrhage in a Patient With Acute Myocardial Infarction Following Primary Percutaneous Coronary Intervention: A Case Report. (PubMed, Cureus) - "Other potential etiologies were ruled out through serological testing. This case highlights DAH as a serious, albeit rare, complication of glycoprotein IIb/IIIa inhibitor therapy and emphasizes the importance of early recognition and immediate drug discontinuation to ensure favorable outcomes."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Pulmonary Disease

Case Report: Severe thrombocytopenia in the context of concomitant tirofiban and ibuprofen use: does ibuprofen matter? (PubMed, Front Cardiovasc Med) - "Alternative analgesics (e.g., acetaminophen/paracetamol) may be considered when pain management is required. If concurrent administration is unavoidable, intensive platelet count monitoring (e.g., every 6-12 h) is imperative during the first 24 h of therapy."

Journal • Cardiovascular • Hematological Disorders • Pain • Thrombocytopenia • Thrombosis

High glucose enhances inflammation-driven platelet adhesion to endothelial cells in vitro. (PubMed, Sci Rep) - "In some experiments, platelets were treated with tirofiban, a GP IIb/IIIa inhibitor, before HAEC exposure...By combining simplicity with reproducibility, the model offers a valuable tool for investigating platelet-endothelium interactions. It also serves as a preclinical platform for evaluating therapeutic interventions aimed at reducing thrombotic risk in conditions of inflammation and hyperglycaemia."

Journal • Preclinical • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • Oncology • TNFA

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (clinicaltrials.gov) - P3 | N=516 | Active, not recruiting | Sponsor: Peking Union Medical College Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2025 ➔ Mar 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2026

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular

The Impact of Cangrelor in the UK for the Treatment of STEMI Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention. (PubMed, J Clin Med) - "Oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban), and aspirin and heparin alone were included as base case comparators. The introduction of cangrelor is estimated to lead to 314 fewer hospital days and 190 clinical events avoided over 5 years. Introducing cangrelor to STEMI patients with gastric absorption issues undergoing PCI in the UK is estimated to generate a small cost saving and reduced length of stay for some patients."

Journal • Cardiovascular • Myocardial Infarction

What the Sigma? Exploring the Change From Single to Dual Anti-Platelet ROTEM on the FIBTEM to Clauss Fibrinogen Relationship in Neurotrauma. (PubMed, Emerg Med Australas) - "Similar relationships between FIBTEM and CF were observed for single and dual anti-platelet FIBTEM systems in TICH. Thresholds for fibrinogen replacement may be generalisable between single and dual anti-platelet FIBTEM systems; however, external validation is necessary."

Journal • Observational data • Retrospective data • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Vascular Neurology

Interventional embolization therapy for anterior choroidal artery aneurysms. (PubMed, Medicine (Baltimore)) - "During interventional embolization surgery, 3 cases experienced choroidal artery thrombosis or spasm, and were treated with tirofiban simultaneously...After active treatment for cerebral infarction, one of them showed improvement in symptoms. Flexibly utilizing intervention techniques to ensure the patency of the anterior choroidal artery is crucial for interventional embolization of AchANs."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Hematological Disorders • Thrombosis

Effect of intravenous tirofiban on the efficacy and safety of stent retriever versus aspiration first-line thrombectomy secondary analysis of the RESCUE BT trial. (PubMed, Int J Surg) - "In RESCUE BT trial, the treatment effect of perioperative intravenous tirofiban was not influenced by the first-line EVT strategy. In both first-line stent retriever thrombectomy and aspiration thrombectomy groups, we observed no significant differences in the clinical outcomes with the adjunctive use of intravenous tirofiban. Randomized controlled trials are needed to confirm these findings."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Reduced hemorrhagic complications of intravenous glycoprotein IIb/IIIa inhibitors in flow diversion for ruptured aneurysms: A single-center study and meta-analysis. (PubMed, Interv Neuroradiol) - "We retrospectively reviewed rIA patients treated with FD at our institution.ResultsTwenty-six studies were included (387 patients): 167 (43.1%) received GPIIb/IIIa-only protocols and 220 (56.9%) received classic AP (predominantly aspirin and clopidogrel). Six received intra-procedural tirofiban, and one received ticagrelor/aspirin. Hemorrhagic and ischemic complications each occurred in 1/7 (14.3%) patients, two (28.6%) died and four (57.1%) achieved modified Rankin Scale ≤ 2 at 90 days.ConclusionsIV GPIIb/IIIa inhibitors administered at FD deployment for rIA are associated with fewer hemorrhagic complications without increased ischemic events and represent a feasible acute management strategy."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

Viscoelastic coagulation testing in bleeding trauma patients: a retrospective analysis and development of a treatment algorithm. (PubMed, Br J Anaesth) - "These ClotPro® cut-off values allow for early and reliable detection of hypofibrinogenaemia and thrombocytopenia. Only after correction of fibrinogen and platelet deficits should prolonged CT be considered a weak marker for the augmentation of coagulation factors."

Journal • Retrospective data • Hematological Disorders • Thrombocytopenia

The efficacy and safety of tirofiban plus thrombolysis and thrombolysis alone for acute ischemic stroke: A meta-analysis. (PubMed, Am J Emerg Med) - "Tirofiban plus thrombolysis was associated with better functional outcomes, but not sICH, aICH, bleeding from other sites, or mortality among patients with AIS compared with thrombolysis only. Further studies should focus on its safety profile and application to target patients."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology

The safety and efficacy of tirofiban therapy after intravenous thrombolysis in patients with acute ischemic stroke: A systematic review and meta-analysis. (PubMed, Clin Neurol Neurosurg) - "Tirofiban administration may be safe and effective in AIS patients, regardless of whether they undergo bridging therapy after intravenous thrombolysis. However, further randomized controlled clinical trials are warranted to validate these findings."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Evaluation of the Efficacy and Safety of Tirofiban in the Treatment of Acute Ischemic Stroke with Non-large Vessel Occlusion beyond the Intravenous Thrombolysis Time Window (ChiCTR) - P=N/A | N=186 | Not yet recruiting | Sponsor: Bozhou People's Hospital; Bozhou People's Hospital

New trial • Cardiovascular • Ischemic stroke

Conservative Management of Non-Obstructive Left Main Coronary Artery Thrombus in the Setting of Myopericarditis (AHA 2025) - "We describe a case in which myopericarditis likely contributed to the formation of a non-obstructive left main coronary artery thrombus in the setting of overlapping systemic inflammation and underlying prothrombotic risk, managed conservatively without percutaneous intervention.Case presentation:A 36-year-old male with a history of well-controlled HIV on ART, presented with fever, hypotension, and a morbilliform rash shortly after initiation of trimethoprim-sulfamethoxazole for a skin and soft tissue infection...The patient was managed with a tirofiban bolus and infusion, a heparin drip, and dual antiplatelet therapy with aspirin and clopidogrel...In patients with non-obstructive coronary thrombus trigerred by a prothrombotic state, conservative management with anticoagulation and antiplatelet therapy may be appropriate in those who are hemodynamically stable. Clinicians should maintain a high index of suspicion for thrombotic complications in patients with systemic..."

Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Hypotension • Infectious Disease • Inflammation • Thrombosis

Tetrastigma hemsleyanum polysaccharides as natural inhibitors of platelet thrombosis via GPIIb/IIIa and MAPK pathways. (PubMed, Phytomedicine) - "THP5 exerts potent antithrombotic effects by directly targeting GPIIb/IIIa and modulating PKCα-MAPK-dependent platelet activation, supporting its potential as a safe and effective therapeutic candidate for thrombotic disorders."

Journal • Cardiovascular • Hematological Disorders • Inflammation • Thrombosis

USE OF TIROFIBAN IN ACUTE LARGE AND SMALL VESSEL OCCLUSION: A CASE SERIES (WSC 2025) - "Tirofiban IV was followed by enoxaparin ± clopidogrel, with stable outcomes. Tirofiban appears to be a safe and flexible option in acute ischemic stroke when MT is not performed or incomplete. It was well tolerated across various scenarios, including elderly, cardioembolic, and posterior circulation strokes. Further research is warranted to define optimal dosing, indications, and outcomes."

Clinical • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis

ACUTE INTRACRANIAL STENTING FOR PEDIATRIC STROKE DUE TO FOCAL CEREBRAL ARTERIOPATHY: A CASE REPORT (WSC 2025) - "After starting dual anti-platelet therapy, endovascular procedure was performed: a Solitaire AB 4x20mm stent-retriever was first deployed to debulk the lesion, followed by release of Pegasus 3.5x15mm stent and tirofiban intravenous infusion, achieving complete recanalization... The literature on intracranial stenting in pediatric patients is limited to a few case reports, primarily involving intracranial arterial dissection following failure of optimal medical management. In this case, an aggressive stenting approach proved both effective and safe. Continued clinical and radiological monitoring is warranted, given the limited data on the long-term outcomes in the pediatric population."

Case report • Clinical • Cardiovascular • CNS Disorders • Giant Cell Arteritis • Pediatrics • Vascular Neurology